Bevacizumab (B) plus immunotherapy (IT) plus chemotherapy (C) (BIC) in metastatic renal cell cancer (mRCC): results and evaluation of circulating T-regulatory cells (Treg) and other cytokines. A GOIRC study / Passalacqua, R; Buti, S; Simonelli, C; Rivoltini, L; Castelli, C; Camisaschi, C; Lo Re, G; Lleshi, A; Donnini, M; Lazzarelli, S. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 21:supplement 8(2010), pp. 285-285.
Bevacizumab (B) plus immunotherapy (IT) plus chemotherapy (C) (BIC) in metastatic renal cell cancer (mRCC): results and evaluation of circulating T-regulatory cells (Treg) and other cytokines. A GOIRC study
Buti S;
2010-01-01
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
